Difficult-to-treat rheumatoid arthritis
Rheumatoid arthritis is the most common inflammatory arthritis and has benefited from significant advances in its management in the past years. However, specific challenges persist, including the management of difficult-to-treat rheumatoid (D2TRA), which is defined by the failure of at least two biological or targeted synthetic disease-modifying antirheumatic drugs with a different mechanism of action. D2TRA reported prevalence is from 5 to 20 %. EULAR (European Alliance of Associations for Rheumatology) proposed a step-by-step approach for managing D2TRA, starting with confirmation of diagnosis, assessment of inflammatory activity, immunosuppressive treatment choice and non-pharmacological treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 20(2024), 865 vom: 13. März, Seite 541-545 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Polyarthrite rhumatoïde difficile à traiter |
|---|
| Beteiligte Personen: |
Alromaih, Fahad Jamal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2024.20.865.541 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369724607 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369724607 | ||
| 003 | DE-627 | ||
| 005 | 20240315234312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2024.20.865.541 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369724607 | ||
| 035 | |a (NLM)38482760 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Alromaih, Fahad Jamal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Difficult-to-treat rheumatoid arthritis |
| 246 | 3 | 3 | |a Polyarthrite rhumatoïde difficile à traiter |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rheumatoid arthritis is the most common inflammatory arthritis and has benefited from significant advances in its management in the past years. However, specific challenges persist, including the management of difficult-to-treat rheumatoid (D2TRA), which is defined by the failure of at least two biological or targeted synthetic disease-modifying antirheumatic drugs with a different mechanism of action. D2TRA reported prevalence is from 5 to 20 %. EULAR (European Alliance of Associations for Rheumatology) proposed a step-by-step approach for managing D2TRA, starting with confirmation of diagnosis, assessment of inflammatory activity, immunosuppressive treatment choice and non-pharmacological treatment | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Dumusc, Alexandre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 20(2024), 865 vom: 13. März, Seite 541-545 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:865 |g day:13 |g month:03 |g pages:541-545 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2024.20.865.541 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 865 |b 13 |c 03 |h 541-545 | ||